

# Xintela obtains US patent for stem cell treatment

**Xintela announces that the US patent office USPTO has today approved the company's patent application for treatment of musculoskeletal diseases using Xintela's stem cell products.**

The USPTO today issued Xintela's patent US 11,517,593 covering stem cell treatment of musculoskeletal diseases including osteoarthritis and other degenerative joint diseases as well as treatment of traumatic joint injuries including damage of articular cartilage, bone, tendons and ligaments. Xintela's patented stem cell treatment consists of integrin  $\alpha 10\beta 1$ -selected mesenchymal stem cells for both humans (XSTEM®), horses (EQSTEM®) and other animals. The patent is valid until the year 2039.

*"This newly approved US patent will together with our previously approved stem cell product patents in Europe and several other countries, be key value driver in our discussions with potential partners and licensees. Our patents secure the continued development and commercialization of XSTEM and our veterinary stem cell products on important markets for many years to come",* says Xintela's CEO Evy Lundgren-Åkerlund.

## Contacts

### **Xintela AB (publ)**

Evy Lundgren-Åkerlund, CEO

Tel: +46 46 275 65 00

Email: [evy@xintela.se](mailto:evy@xintela.se)

Medicon Village

223 81 Lund, Sweden

[www.xintela.se](http://www.xintela.se)



---

## About Xintela

---

Xintela develops medical products in stem cell therapy and targeted cancer therapy based on the Company's cell surface marker integrin  $\alpha 10\beta 1$  which is found on mesenchymal stem cells and on certain aggressive cancer cells. The stem cell marker is used to select and quality-assure the patent-protected stem cell product XSTEM®, which is in clinical development for treatment of knee osteoarthritis and difficult-to-heal leg ulcers. The company produces XSTEM for the clinical studies in its GMP-approved manufacturing facility. In cancer therapy, which is run by the wholly owned subsidiary Targinta AB, therapeutic antibodies, targeting integrin  $\alpha 10\beta 1$  (First-in-Class) are being developed for the treatment of triple-negative breast cancer and the brain tumor glioblastoma. Xintela conducts its business at Medicon Village in Lund, Sweden, and is listed on Nasdaq First North Growth Market Stockholm since 22 March 2016. Xintela's Certified Adviser at Nasdaq First North Growth Market is Erik Penser Bank AB, +46 8-463 80 00, [certifiedadviser@penser.se](mailto:certifiedadviser@penser.se).

## Attachments

---

[Xintela obtains US patent for stem cell treatment](#)